- Home
- BLIN vs LPCN Comparison
BLIN vs LPCN Comparison
Compare BLIN & LPCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BLIN
- LPCN
- Stock Information
- Founded
- BLIN 2000
- LPCN 1997
- Country
- BLIN United States
- LPCN United States
- Employees
- BLIN N/A
- LPCN N/A
- Industry
- BLIN EDP Services
- LPCN Biotechnology: Pharmaceutical Preparations
- Sector
- BLIN Technology
- LPCN Health Care
- Exchange
- BLIN Nasdaq
- LPCN Nasdaq
- Market Cap
- BLIN 16.0M
- LPCN 16.1M
- IPO Year
- BLIN 2007
- LPCN N/A
- Fundamental
- Price
- BLIN $1.55
- LPCN $3.22
- Analyst Decision
- BLIN Strong Buy
- LPCN Strong Buy
- Analyst Count
- BLIN 1
- LPCN 1
- Target Price
- BLIN $4.62
- LPCN $10.00
- AVG Volume (30 Days)
- BLIN 74.7K
- LPCN 10.3K
- Earning Date
- BLIN 05-13-2025
- LPCN 05-08-2025
- Dividend Yield
- BLIN N/A
- LPCN N/A
- EPS Growth
- BLIN N/A
- LPCN N/A
- EPS
- BLIN N/A
- LPCN N/A
- Revenue
- BLIN $15,394,000.00
- LPCN $11,198,144.00
- Revenue This Year
- BLIN $4.89
- LPCN N/A
- Revenue Next Year
- BLIN $10.49
- LPCN N/A
- P/E Ratio
- BLIN N/A
- LPCN N/A
- Revenue Growth
- BLIN N/A
- LPCN N/A
- 52 Week Low
- BLIN $0.76
- LPCN $2.75
- 52 Week High
- BLIN $2.80
- LPCN $11.79
- Technical
- Relative Strength Index (RSI)
- BLIN 51.45
- LPCN 46.55
- Support Level
- BLIN $1.46
- LPCN $2.82
- Resistance Level
- BLIN $1.60
- LPCN $3.27
- Average True Range (ATR)
- BLIN 0.11
- LPCN 0.22
- MACD
- BLIN -0.00
- LPCN 0.01
- Stochastic Oscillator
- BLIN 66.67
- LPCN 58.92
About BLIN Bridgeline Digital Inc.
Bridgeline Digital Inc is a AI-powered marketing technology company that offers a suite of products that help companies grow online revenue by driving more traffic to their websites, converting more visitors to purchasers, and increasing average order value. Company software is available through a cloud-based Software as a Service (SaaS) model. It helps to maximize the performance of critical websites, intranets, and online stores. The company generates revenue from digital engagement services, subscription, perpetual licenses, maintenance, and hosting. Geographically, it derives a majority of revenue from the United States.
About LPCN Lipocine Inc.
Lipocine Inc is a clinical-stage biopharmaceutical company, that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP'RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.